Table 2. Patients' characteristics (N=466).

Characteristics	Numbers (%)
Male:female	237 (50.9%):229 (49.1%)
Age at first injection of palivizumab (month)	2.9±2.8 (range, 0–11.2)
Mean doses of palivizumab underwent cardiovascular surgery (n=442)	3.7±1.9 (range, 1–10) (94.8%)
Co-Morbidities
Prematurity	35 (7.5%)
Low birth weight	33 (7.1%)
Chromosomal anomalies or syndromes	65 (13.9%)
RSV bronchiolitis	57 (12.2%)
Respiratory infection associated with other viruses requiring in-hospitalization treatment	40 (8.6%)
Total deaths	30 (6.4%)

RSV: respiratory syncytial virus